J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Short Communication

Volume 3, Number 5, October 2011, pages 252-257

Influence of Physical Activity Intervention on Circulating Soluble Receptor for Advanced Glycation end Products in Elderly Subjects

**Table 1.** Clinical Characteristics in the Pre- to Post-phase of Intervention
Variable	Pre-phase	Post-phase	P value
LDL: low-density lipoprotein; HDL: high-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; PON1: paraoxonase1; RAGE: the receptor for advanced glycation end products.Data are expressed as the means ± standard deviations or the medians (interquartile ranges).Significance level (difference between the pre- and post-phase data by a paired t-test [triglycerides, insulin and HOMA-IR were log-transformed]): *P < 0.05.
Body mass index, kg/m²	23.6 ± 2.4	23.4 ± 2.5	0.018*
Systolic blood pressure, mmHg	137.1 ± 17.1	136.9 ± 21.1	0.948
Diastolic blood pressure, mmHg	78.6 ± 11.5	79.8 ± 11.5	0.336
LDL-cholesterol, mmol/L	3.47 ± 0.71	3.28 ± 0.70	0.072
Triglycerides, mmol/L	1.19 (0.80-1.43)	1.14 (0.83-1.47)	0.502
HDL-cholesterol, mmol/L	1.83 ± 0.39	1.83 ± 0.39	0.883
Fasting plasma glucose, mmol/L	5.33 ± 0.53	5.25 ± 0.58	0.386
Insulin, µU/mL	4.5 (3.7-6.8)	5.0 (3.7-6.2)	0.749
HOMA-IR	1.15 (0.80-1.62)	1.20 (0.88-1.40)	0.626
PON1, U/L	161.3 ± 49.5	160.6 ± 50.0	0.870
Soluble RAGE, ng/L	1103 ± 496	1030 ± 437	0.019*

Table 1. Clinical Characteristics in the Pre- to Post-phase of Intervention

Variable

Pre-phase

Post-phase

P value

LDL: low-density lipoprotein; HDL: high-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; PON1: paraoxonase1; RAGE: the receptor for advanced glycation end products.Data are expressed as the means ± standard deviations or the medians (interquartile ranges).Significance level (difference between the pre- and post-phase data by a paired t-test [triglycerides, insulin and HOMA-IR were log-transformed]): *P < 0.05.

Body mass index, kg/m²

23.6 ± 2.4

23.4 ± 2.5

0.018*

Systolic blood pressure, mmHg

137.1 ± 17.1

136.9 ± 21.1

0.948

Diastolic blood pressure, mmHg

78.6 ± 11.5

79.8 ± 11.5

0.336

LDL-cholesterol, mmol/L

3.47 ± 0.71

3.28 ± 0.70

0.072

Triglycerides, mmol/L

1.19 (0.80-1.43)

1.14 (0.83-1.47)

0.502

HDL-cholesterol, mmol/L

1.83 ± 0.39

0.883

Fasting plasma glucose, mmol/L

5.33 ± 0.53

5.25 ± 0.58

0.386

Insulin, µU/mL

4.5 (3.7-6.8)

5.0 (3.7-6.2)

0.749

HOMA-IR

1.15 (0.80-1.62)

1.20 (0.88-1.40)

0.626

PON1, U/L

161.3 ± 49.5

160.6 ± 50.0

0.870

Soluble RAGE, ng/L

1103 ± 496

1030 ± 437

0.019*

**Table 2.** Correlations of Soluble RAGE With Other Variables
Variable	Pre-phase	Pre- and post-change
RAGE: the receptor for advanced glycation end product; LDL: low-density lipoprotein; HDL: high-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; PON1: paraoxonase1; Pre-phase: correlation between the pre-phase data in respective variables; Pre- and post-change: correlation between the level changes (the post-phase data minus the pre-phase data) in respective variables (age and gender used the pre-phase data were); r: simple linear regression coefficient between soluble RAGE and another variable; β: multiple linear regression coefficient in a stepwise multivariate analysis for soluble RAGE after controlling for all the listed variables (except for HOMA-IR).Triglycerides, insulin and HOMA-IR were log-transformed for the analyses.Significance level: P < 0.05; *P < 0.01.
Age, years	0.068 (0.722)	0.188 (0.318)
Gender, male	-0.063 (0.742)	0.011 (0.955)
Body mass index, kg/m²	-0.512 (0.004)**	-0.191 (0.313)
Systolic blood pressure, mmHg	0.048 (0.800)	0.135 (0.476)
Diastolic blood pressure, mmHg	-0.071 (0.710)	0.174 (0.358)
LDL-cholesterol, mmol/L	-0.080 (0.673)	-0.230 (0.221)
Triglycerides, mmol/L	-0.050 (0.792)	0.123 (0.516)
HDL-cholesterol, mmol/L	-0.154 (0.418)	-0.189 (0.317)
Fasting plasma glucose, mmol/L	-0.021 (0.912)	-0.030 (0.874)
Insulin, µU/mL	-0.290 (0.120)	0.041 (0.829)
HOMA-IR	-0.365 (0.047)*	-0.013 (0.944)
PON1, UL	-0.166 (0.381)	-0.511 (0.004)**

Table 2. Correlations of Soluble RAGE With Other Variables

Variable

Pre-phase

Pre- and post-change

r (P value)

RAGE: the receptor for advanced glycation end product; LDL: low-density lipoprotein; HDL: high-density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance; PON1: paraoxonase1; Pre-phase: correlation between the pre-phase data in respective variables; Pre- and post-change: correlation between the level changes (the post-phase data minus the pre-phase data) in respective variables (age and gender used the pre-phase data were); r: simple linear regression coefficient between soluble RAGE and another variable; β: multiple linear regression coefficient in a stepwise multivariate analysis for soluble RAGE after controlling for all the listed variables (except for HOMA-IR).Triglycerides, insulin and HOMA-IR were log-transformed for the analyses.Significance level: *P < 0.05; **P < 0.01.

Age, years

0.068 (0.722)

0.188 (0.318)

Gender, male

-0.063 (0.742)

0.011 (0.955)

Body mass index, kg/m²

-0.512 (0.004)**

-0.191 (0.313)

Systolic blood pressure, mmHg

0.048 (0.800)

0.135 (0.476)

Diastolic blood pressure, mmHg

-0.071 (0.710)

0.174 (0.358)

LDL-cholesterol, mmol/L

-0.080 (0.673)

-0.230 (0.221)

Triglycerides, mmol/L

-0.050 (0.792)

0.123 (0.516)

HDL-cholesterol, mmol/L

-0.154 (0.418)

-0.189 (0.317)

Fasting plasma glucose, mmol/L

-0.021 (0.912)

-0.030 (0.874)

Insulin, µU/mL

-0.290 (0.120)

0.041 (0.829)

HOMA-IR

-0.365 (0.047)*

-0.013 (0.944)

PON1, UL

-0.166 (0.381)

-0.511 (0.004)**